Evidence map›Paper›PMID 32384683›Full record

ArticleInternational journal of molecular sciences2020

An 5 GABAA Receptor Inverse Agonist, 5IA, Attenuates Amyloid Beta-Induced Neuronal Death in Mouse Hippocampal Cultures.

Chitra Vinnakota, Karan Govindpani, Warren Perry Tate, Katie Peppercorn, Praju Vikas Anekal, Henry John Waldvogel, Richard Lewis Maxwell Faull, Andrea Kwakowsky

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Beta-Amyloid (AβMolecules (Basel, Switzerland) · 2022
    Article
  4. Article
  5. Review
  6. Article
  7. The Interplay Between Beta-Amyloid 1-42 (AβFrontiers in molecular neuroscience · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Chitra VinnakotaCentre for Brain Research, Department of Anatomy and Medical Imaging, Faculty of Medical and Health, Sciences, University of Auckland, Auckland 1023, New Zealand.
Karan GovindpaniCentre for Brain Research, Department of Anatomy and Medical Imaging, Faculty of Medical and Health, Sciences, University of Auckland, Auckland 1023, New Zealand.
Warren Perry TateDepartment of Biochemistry, University of Otago, Dunedin 9054, New Zealand.
Katie PeppercornDepartment of Biochemistry, University of Otago, Dunedin 9054, New Zealand.
Praju Vikas AnekalBiomedical Imaging Research Unit, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1023, New Zealand.
Henry John WaldvogelCentre for Brain Research, Department of Anatomy and Medical Imaging, Faculty of Medical and Health, Sciences, University of Auckland, Auckland 1023, New Zealand.
Richard Lewis Maxwell FaullCentre for Brain Research, Department of Anatomy and Medical Imaging, Faculty of Medical and Health, Sciences, University of Auckland, Auckland 1023, New Zealand.
Andrea KwakowskyCentre for Brain Research, Department of Anatomy and Medical Imaging, Faculty of Medical and Health, Sciences, University of Auckland, Auckland 1023, New Zealand.
University of Auckland · NZUniversity of Otago · NZ

Funding

Alzheimers New Zealand 3718869Alzheimers New Zealand Charitable Trust 3720863Aotearoa Foundation, Centre for Brain Research, University of Auckland 3705579Brain Research New Zealand NAFreemasons New Zealand 3719321Health Research Council of New Zealand 3627373
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder for which no cognition-restoring therapies exist. Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the brain. Increasing evidence suggests a remodeling of the GABAergic system in AD, which might represent an important therapeutic target. An inverse agonist of 5 subunit-containing GABAA receptors (α5GABAARs), 3-(5-Methylisoxazol-3-yl)-6-[(1-methyl-1,2,3-triazol-4-yl)methyloxy]-1,2,4-triazolo[3-

Indexed as

Amyloid beta-PeptidesAnimalsCell DeathCells, CulturedGABA-A Receptor AgonistsGABAergic NeuronsHippocampusMaleMiceMice, Inbred C57BLNeuroprotective AgentsPeptide FragmentsPhthalazinesReceptors, GABA-ASynaptic TransmissionTriazoles3-(5-methylisoxazol-3-yl)-6-((1-methyl-1,2,3-triazol-4-yl)methyloxy)-1,2,4-triazolo(3,4-a)phthalazineAmyloid beta-Peptidesamyloid beta-protein (1-42)GABA-A Receptor AgonistsNeuroprotective AgentsPeptide FragmentsPhthalazinesReceptors, GABA-ATriazoles5 GABAA receptors5IAAlzheimer’s diseaseGABA

Identifiers

PMID32384683
PMCPMC7247548
OpenAlexW3023602342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.